TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Not Specified
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results

Cytek Biosciences announced preliminary Q4 2025 revenue of approximately $62 million, representing 8% year-over-year growth and 19% sequential growth. Full year 2025 revenue is expected to be approximately $201 million. The company highlighted strong growth in Services, Reagents, and Asia Pacific instrument revenue, along with improved instrument sales in the US and EMEA regions, particularly a return to positive growth in EMEA.

Insights
CTKB   positive

The company reported meaningful acceleration in Q4 growth (8% YoY, 19% QoQ), positive trends across multiple business segments (Services, Reagents, Asia Pacific), and a return to positive instrument growth in EMEA. Management expressed confidence in sustainable growth and profitability prospects in the flow cytometry market.